Skip to content

The effect of pentoxifylline in the treatment of Covid-19 disease

Evaluation of pentoxifylline effect in treatment of patients with COVID-19, hospitalized in an intensive care unit, A randomized clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110425006280N11
Enrollment
20
Registered
2021-01-27
Start date
2021-01-19
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of pentoxifylline in the treatment of covid-19 disease. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: This study is performed in critically ill patients with COVID-19 admitted to Razi Hospital after obtaining informed consent from the patient or their companions.The

Sponsors

Vice President of Research Guilan university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with a clinical diagnosis of respiratory distress and dyspnea with SPAO2 less than 93% or positive PCR and radiographic test on CT SCANNING or Chest X-Ray admitted to the intensive care unit

Exclusion criteria

Exclusion criteria: pregnant patients patients who get under therapy for less than 3 days

Design outcomes

Primary

MeasureTime frame
Clinical signs of COVID-19 disease. Timepoint: Daily in the morning visit for 14 days. Method of measurement: Observe, measure and record fever, cough, shortness of breath, olfactory and taste disorders, headache, gastrointestinal symptoms, chills and .;Percentage of oxygen saturation. Timepoint: Daily in the morning visit for 14 days. Method of measurement: Based on measurements with pulse oximetery.

Secondary

MeasureTime frame
Patient`s recovery. Timepoint: Daily in the morning visit for 14 days. Method of measurement: No need for supplemental oxygen or mechanical ventilation and ICU discharge.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Haghighi

Guilan University of Medical Sciences

manesthesist@gmail.com+98 13 1322 3970

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026